PDE4A and psoriasis: Apremilast, a PDE4 inhibitor, demonstrates efficacy across diverse psoriasis types, including specialty sites (e.g., scalp, nails) and pediatric patients, with mild, transient side effects (e.g., nausea, diarrhea, headache) and low discontinuation rates (119, 166, 167).